Related Experiment Videos
Beta-agonist aerosol distribution in respiratory syncytial virus bronchiolitis in infants
Israel Amirav1, Ivgenia Balanov, Miguel Gorenberg
1Department of Pediatric Pulmonology, Rebecca Sieff Governmental Hospital, Safed, Israel.
Insights
Bronchodilator aerosol delivery to infants with bronchiolitis is largely ineffective due to poor lung deposition. Improvements in targeting narrowed airways with superfine aerosols are needed for better treatment outcomes in this pediatric population.
Area of Science:
- Pediatric Pulmonology
- Respiratory Medicine
- Medical Imaging
Background:
- Bronchodilator aerosols are commonly used for infant bronchiolitis but show limited efficacy.
- Effective aerosol treatment relies on precise delivery to inflamed airways.
- This study investigates aerosol distribution in infants with acute bronchiolitis.
Purpose of the Study:
- To evaluate the lower respiratory tract distribution of nebulized bronchodilators in infants with acute bronchiolitis.
- To assess factors influencing aerosol deposition in the lungs of infants.
- To identify potential areas for improving aerosol delivery techniques in this age group.
Main Methods:
- Twelve infants with acute respiratory syncytial virus bronchiolitis were included.
- Technetium-99m-labeled albuterol aerosol was administered.
- Gamma-scintigraphy was employed to measure total body, lung, and regional pulmonary deposition.
Main Results:
- Only 1.5% of the nebulized dose reached the right lung, with 0.6% reaching the peripheral lung zone.
- Significant deposition occurred in the upper respiratory and gastrointestinal tracts (7.8%) and on the face (10%-12%).
- No correlation was observed between deposition indices and clinical response or demographic factors.
Conclusions:
- Poor aerosol deposition in infants may stem from small airway size and the disease state.
- Current aerosol delivery methods offer substantial room for improvement in infants.
- Future strategies should focus on targeting peripheral airways with superfine aerosols for enhanced efficacy.
Unlabelled:
Bronchodilator aerosols are frequently administered to infants with bronchiolitis but with little success. The efficacy of aerosol treatments depends mainly on adequate targeting of the aerosol particles to the inflamed airways. This study evaluated the lower respiratory tract distribution characteristics of nebulized bronchodilators in infants with acute bronchiolitis.
Methods:
Twelve infants (mean age +/- SD, 8 mo +/- 4 mo) who were admitted for acute respiratory syncytial virus bronchiolitis were treated with (99m)Tc-albuterol aerosol. Gamma-scintigraphy was used to assess total body and lung deposition as well as pulmonary distribution of the medication.
Results:
Of the total 6-min nebulized dose (i.e., drug aerosol dose leaving the nebulizer [not the nebulizer charge]), 1.5% +/- 0.7% reached the right lung, with only approximately one third of that (0.6%) penetrating to the peripheral lung zone. There was 7.8% +/- 4.9% deposition in the upper respiratory and gastrointestinal tracts and 10%-12% remained on the face. No correlation was found between any of the deposition indices and the clinical response data or any of the demographic parameters (e.g., height, weight, body surface area, or clinical score).
Conclusion:
Poor total aerosol deposition in infants may be related as much to their small conducting airways as to the disease state. There is considerable room for improvement in aerosol delivery in this age group, with greater emphasis on targeting narrowed peripheral airways with superfine aerosols.